Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus

The Journal of Clinical Endocrinology and Metabolism
Chia-Hsuin ChangLee-Ming Chuang

Abstract

Hyperinsulinemia might be the mechanism leading to an increased cancer risk in patients with type 2 diabetes. The objective was to evaluate the association between oral insulin secretagogues, insulins, and cancer incidence. A total of 108,920 patients with newly diagnosed type 2 diabetes were identified from the Taiwan National Health Insurance claims database during the period from 1 January 2000 to 31 December 2000. As of 31 December 2007, patients with incident cancer were included as cases, and up to four age- and sex-matched controls were selected by risk-set sampling. Logistic regression models were applied to estimate the odds ratio (OR) and 95% confidence interval (CI) between antidiabetic medication and cancer incidence. A total of 8,194 incident cancer cases and 32,776 diabetic controls were included. A significantly increased risk for overall cancer incidence was found for any use of insulin (OR, 1.97; 95% CI, 1.85-2.09) and glinides (OR, 1.16; 95% CI, 1.06-1.28). Significantly increased risks were found for first- and second-generation sulfonylureas (OR, 1.08; 95% CI, 1.01-1.15), but not for third-generation drug, glimepiride (OR, 1.00; 95% CI, 0.93-1.08). Use of insulin and glinides was associated with higher risks...Continue Reading

Citations

Dec 29, 2012·Current Diabetes Reports·Etan Orgel, Steven D Mittelman
May 31, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S SchlesingerU Nöthlings
Aug 14, 2013·Nature Reviews. Gastroenterology & Hepatology·Siddharth SinghWilliam Sanchez
Feb 25, 2014·Current Diabetes Reports·Peter M Thulé, Guillermo Umpierrez
Jul 16, 2014·Pathology, Research and Practice·Bianka BojkováKarol Kajo
Oct 2, 2014·Expert Opinion on Drug Safety·Jocelyn de Heer, Burkhard Göke
Apr 29, 2015·Acta Diabetologica·Esther García-EsquinasMarina Pollán
Sep 21, 2013·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Yaa-Hui DongMei-Shu Lai
Feb 26, 2016·British Journal of Cancer·Custodia García-JiménezAntonio De la Vieja
May 21, 2014·Journal of Diabetes Investigation·Hiroshi NotoMitsuhiko Noda
Apr 12, 2013·Pharmacoepidemiology and Drug Safety·Chia-Lin HsuMei-Shu Lai
Apr 12, 2013·Journal of Diabetes·Tiange WangZachary Bloomgarden
May 21, 2014·Journal of Diabetes Investigation·Shi SenKeizo Kanasaki
May 7, 2015·Cell Cycle·Olga PivovarovaNatalia Rudovich
Jul 1, 2015·Liver International : Official Journal of the International Association for the Study of the Liver·Hamza ChettouhChristèle Desbois-Mouthon
Jun 16, 2015·Gastroenterology Research and Practice·Luca MieleAntonio Grieco
Jun 9, 2016·International Journal of Environmental Research and Public Health·Yunjuan GuShiwei Cui
Nov 3, 2016·Nature Reviews. Clinical Oncology·Adi J Klil-DroriMichael N Pollak
Dec 3, 2014·The Medical Clinics of North America·Stephen A Brietzke
Dec 1, 2017·Frontiers in Endocrinology·Roberta MalaguarneraAntonino Belfiore
Jan 31, 2018·BioMed Research International·Xu LiPujun Gao
Feb 11, 2018·Clinical Chemistry and Laboratory Medicine : CCLM·Emanuela AnastasiSusanna Morano
Feb 6, 2013·The American Journal of Gastroenterology·Siddharth SinghWilliam Sanchez
Jul 28, 2017·Expert Opinion on Drug Safety·Marco TuccoriCorrado Blandizzi
Dec 14, 2019·Journal of Experimental & Clinical Cancer Research : CR·Muhamad Noor Alfarizal KamarudinIshwar Parhar
Feb 9, 2020·Journal of Clinical Medicine·Audrius DulskasGiedre Smailyte
Jun 6, 2020·Cells·Swayam Prakash Srivastava, Julie E Goodwin
Jun 19, 2013·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Hiroshi NotoMitsuhiko Noda
Feb 19, 2019·International Journal of Endocrinology·Fernanda VacanteIleana Terruzzi

❮ Previous
Next ❯

Related Concepts

Related Feeds